Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II

2012 ◽  
Vol 22 (5) ◽  
pp. 687-694 ◽  
Author(s):  
Rudolf Autrata ◽  
Inka Krejčířová ◽  
Kateřina Šenková ◽  
Marie Holoušová ◽  
Zdeněk Doležel ◽  
...  
Keyword(s):  
Laser Therapy ◽  
Diode Laser ◽  
Retinopathy Of Prematurity ◽  
Zone Ii

scholarly journals Transscleral vs transpupillary diode laser photocoagulation for the treatment of zone II type 1 retinopathy of prematurity: Anatomical and refractive outcomes

2022 ◽  
Vol 70 (1) ◽  
pp. 189
Author(s):  
Nazanin Ebrahimiadib ◽  
Ramak Roohipourmoallai ◽  
Shahin Faghihi ◽  
Hooshang Faghihi ◽  
Ali Torkashvand ◽  
...  
Keyword(s):  
Diode Laser ◽  
Retinopathy Of Prematurity ◽  
Laser Photocoagulation ◽  
Refractive Outcomes ◽  
Zone Ii

Comparison of Refractive Error Changes in Retinopathy of Prematurity Patients Treated with Diode and Red Lasers

2016 ◽  
Vol 235 (3) ◽  
pp. 173-178 ◽  
Author(s):  
Ramak Roohipoor ◽  
Reza Karkhaneh ◽  
Mohammad Riazi Esfahani ◽  
Fateme Alipour ◽  
Mahtab Haghighat ◽  
...  
Keyword(s):  
Birth Weight ◽  
Laser Treatment ◽  
Diode Laser ◽  
Refractive Error ◽  
Gestational Age ◽  
Retinopathy Of Prematurity ◽  
Disease Stage ◽  
Myopic Shift ◽  
Zone Ii ◽  
The Mean

Aim: To compare refractive error changes in retinopathy of prematurity (ROP) patients treated with diode and red lasers. Methods: A randomized double-masked clinical trial was performed, and infants with threshold or prethreshold type 1 ROP were assigned to red or diode laser groups. Gestational age, birth weight, pretreatment cycloplegic refraction, time of treatment, disease stage, zone and disease severity were recorded. Patients received either red or diode laser treatment and were regularly followed up for retina assessment and refraction. The information at month 12 of corrected age was considered for comparison. Results: One hundred and fifty eyes of 75 infants were enrolled in the study. Seventy-four eyes received diode and 76 red laser therapy. The mean gestational age and birth weight of the infants were 28.6 ± 3.2 weeks and 1,441 ± 491 g, respectively. The mean baseline refractive error was +2.3 ± 1.7 dpt. Posttreatment refraction showed a significant myopic shift (mean 2.6 ± 2.0 dpt) with significant difference between the two groups (p < 0.001). There was a greater myopic shift among children with zone I and diode laser treatment (mean 6.00 dpt) and a lesser shift among children with zone II and red laser treatment (mean 1.12 dpt). The linear regression model, using the generalized estimating equation method, showed that the type of laser used has a significant effect on myopic shift even after adjustment for other variables. Conclusion: Myopic shift in laser-treated ROP patients is related to the type of laser used and the involved zone. Red laser seems to cause less myopic shift than diode laser, and those with zone I involvement have a greater myopic shift than those with ROP in zone II.

Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

2020 ◽  
pp. 163-168
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab ◽  
Peripheral Retina ◽  
Controlled Clinical Trial ◽  
Disease Development ◽  
Retinal Vessels ◽  
Randomized Controlled Clinical Trial ◽  
Zone Ii ◽  
Conventional Laser

The Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study was a randomized, controlled clinical trial to determine whether intravitreal bevacizumab monotherapy was an effective therapy for treating zone I or zone II posterior stage 3+ (stage 3 with plus disease) retinopathy of prematurity (ROP). Intravitreal bevacizumab, as compared with conventional laser therapy, showed a significant benefit for zone I but not zone II disease. Development of peripheral retinal vessels (with possible recurrence of ROP) continued after treatment with intravitreal bevacizumab, but conventional laser therapy led to permanent destruction of the peripheral retina.

scholarly journals COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY

Retina ◽  
2017 ◽  
Vol 37 (4) ◽  
pp. 710-717 ◽  
Author(s):  
Guoming Zhang ◽  
Mingmin Yang ◽  
Jian Zeng ◽  
Georgios Vakros ◽  
Kangjin Su ◽  
...  
Keyword(s):  
Intravitreal Injection ◽  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Zone Ii

Indocyanine green-augmented diode laser therapy of telangiectatic and reticular leg veins: a clinical proof-of-concept trial

2012 ◽  
Vol 25 (01) ◽  
Author(s):  
A Klein ◽  
G Shafirstein ◽  
E Kohl ◽  
W Bäumler ◽  
M Landthaler ◽  
...  
Keyword(s):  
Indocyanine Green ◽  
Laser Therapy ◽  
Diode Laser ◽  
Proof Of Concept
Sign in / Sign up

Export Citation Format

Share Document